Paradigm Therapeutics, Inc. announces the first patient to be enrolled in a phase 3 trial for SD-101 (ZorblesiaTM) in bubble epidermolysis

Summary

SD-101 (ZorblesiaTM) is the first topical treatment developed to treat wounds and lesions on the entire skin surface in patients with the three main subtypes of bubble epidermolysis...